Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
Contenu indisponible. Consultez la source originale.
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.